CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 160 enrolled
Drug / intervention
4mg CLS-TA Suprachoriodal Injection +1 moredrug
Likely dose
4mg CLS-TA Suprachoriodal Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02595398
NCT02595398Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis

Clearside Biomedical, Inc.·interventional·Posted Nov 3, 2015·Updated May 28, 2021

In Brief

A Phase 3 clinical trial evaluating 4mg CLS-TA Suprachoriodal Injection and Sham Procedure for Uveitis and 4 related conditions. Completed, enrolled 160 participants across 64 sites in 3 countries.

Detailed Summary

The study is designed to evaluate the safety and efficacy of suprachoroidally administered triamcinolone acetonide, CLS-TA, in subjects with macular edema associated with non-infectious uveitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
CountriesIndia, Israel, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 3, 2015
Enrollment StartNov 17, 2015
Primary CompletionJan 18, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.7 years ago

Interventions

4mg CLS-TA Suprachoriodal Injectiondrug

CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints

Sham Proceduredrug

Sham procedure administered at 2 timepoints